A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

被引：275

作者：

Borasio, GD

Robberecht, W

Leigh, PN

Emile, J

Guiloff, RJ

Jerusalem, F

Silani, V

Vos, PE

Wokke, JHJ

Dobbins, T

机构：

[1] Univ Munich, Dept Neurol, D-80539 Munich, Germany

[2] Katholieke Univ Leuven, Dept Neurol, B-3001 Leuven, Belgium

[3] Inst Psychiat, Dept Clin Neurosci, London, England

[4] Univ London Kings Coll, Sch Med & Dent, London, England

[5] Univ Amsterdam, Acad Med Ctr, Lab Expt Neurol, NL-1105 AZ Amsterdam, Netherlands

[6] Univ Angers, Med Ctr, Dept Neurol B, Angers, France

[7] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany

[8] Charing Cross Hosp, Neuromuscular Unit, London, England

[9] Univ Milan, IRCCS, Osped Maggiore, Dept Neurol, I-20122 Milan, Italy

[10] Univ Utrecht, Div Neuromuscular Dis, NL-3508 TC Utrecht, Netherlands

[11] Cephalon Inc, W Chester, PA USA

来源：

NEUROLOGY | 1998年 / 51卷 / 02期

关键词：

D O I：

10.1212/WNL.51.2.583

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

引用

页码：583 / 586

页数：4

共 11 条

[1] A RATING-SCALE FOR AMYOTROPHIC-LATERAL-SCLEROSIS - DESCRIPTION AND PRELIMINARY EXPERIENCE [J].